Published in J Cardiovasc Surg (Torino) on August 14, 1978
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Impact of a policy of direct admission to a coronary care unit on use of thrombolytic treatment. Br Heart J (1989) 4.62
Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation (2001) 4.32
Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. Br Heart J (1985) 2.92
Cardiac troponin T. Lancet (1993) 2.13
Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther (1999) 2.06
Normal catecholamine production in a patient with a paroxysmally secreting phaeochromocytoma. Ann Clin Biochem (1991) 1.91
Receptor-mediated low density lipoprotein catabolism in man. J Lipid Res (1979) 1.88
Leg-vein thrombosis following myocardial infarction. Lancet (1970) 1.85
The genetic determination of left ventricular mass in healthy adults. Eur Heart J (2003) 1.77
Electrocardiographic prediction of coronary artery patency after thrombolytic treatment in acute myocardial infarction: use of the ST segment as a non-invasive marker. Br Heart J (1988) 1.75
Association between antibodies to heat shock protein 65 and coronary atherosclerosis. Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J (1998) 1.71
A general practitioner electrocardiogram service. Scott Med J (1967) 1.69
"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic. Br Med J (Clin Res Ed) (1984) 1.69
Prophylactic antibiotics in intensive therapy: experience in a cardiac surgical unit. Br J Surg (1970) 1.67
Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J (1999) 1.64
3 and 12 lead electrocardiogram interpretation by computer. A comparison on 1093 patients. Br Heart J (1971) 1.56
Blood pressure in a Scottish island community. Br Med J (1969) 1.50
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation (1997) 1.47
Blood pressure and catecholamine responses to 'stress' in normotensive and hypertensive subjects. Cardiovasc Res (1971) 1.43
Relation between extent of coronary artery disease and blood viscosity. Br Med J (1980) 1.42
Effects of nadolol on arrhythmias during laparoscopy performed under general anaesthesia. Br J Anaesth (1988) 1.41
Assessment by general practitioners of suitability of thrombolysis in patients with suspected acute myocardial infarction. Br Heart J (1993) 1.40
Cardiology: the development of a managed clinical network. BMJ (2000) 1.34
Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. J Clin Invest (1984) 1.29
Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation (1993) 1.26
Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J (1992) 1.22
Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction. Lancet (1990) 1.20
Low density lipoprotein metabolism in a family of familial hypercholesterolemic patients. Metabolism (1976) 1.12
A prospective randomized trial of tocainide in patients following myocardial infarction. Am Heart J (1980) 1.11
The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction. Eur Heart J (1985) 1.11
Relation between extent of coronary artery disease and severity of hyperlipoproteinaemia. Br Heart J (1975) 1.10
Wide variation in the use of thrombolytic therapy among junior doctors in south and central Scotland. Health Bull (Edinb) (1996) 1.09
Beta blockers and verapamil: a cautionary tale. Br Med J (Clin Res Ed) (1984) 1.08
Leucocyte ascorbic acid levels after acute myocardial infarction. Br Heart J (1972) 1.08
Heart rate variability in left ventricular hypertrophy. Br Heart J (1995) 1.07
Left ventricular hypertrophy and mortality in hypertension: an analysis of data from the Glasgow Blood Pressure Clinic. J Hypertens (1990) 1.07
Haemodynamic effects of prenalterol in patients with coronary heart disease. Br Heart J (1980) 1.07
The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation. Br J Clin Pharmacol (1992) 1.06
Evaluation of thallium-201 exercise scintigraphy in coronary heart disease. Br Heart J (1979) 1.01
Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut (1984) 1.00
ABC of sports medicine. Sudden death in sport. BMJ (1994) 0.99
Alcoholic ketoacidosis: a case report. Scott Med J (1987) 0.99
Familial pattern of corticosteroids and their metabolism in adult human subjects--the Scottish Adult Twin Study. J Clin Endocrinol Metab (1999) 0.98
Questionnaire survey of thrombolytic treatment in accident and emergency departments in the United Kingdom. BMJ (1998) 0.97
Comparison of enalapril and atenolol in mild to moderate hypertension. Am J Med (1989) 0.96
Prevalence of hyperlipoproteinaemia in apparently healthy men. Br Heart J (1974) 0.96
Intracoronary thrombolytic therapy performed within a coronary care unit: one year's experience. Scott Med J (1986) 0.96
Exercise prescription in adults with congenital heart disease: a long way to go. Heart (2000) 0.96
Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens (1992) 0.94
The long-term management of the patient with an aortic coarctation repair. Eur Heart J (1998) 0.94
Antiarrhythmic drugs. Br Med J (Clin Res Ed) (1983) 0.94
Electrophysiological effects of felodipine. Drugs (1985) 0.93
The ergoreflex in patients with chronic stable heart failure. Int J Cardiol (1999) 0.93
Oral verapamil does not affect glucose tolerance in non-diabetics. Br J Clin Pharmacol (1983) 0.92
Increased blood viscosity and fibrinolytic inhibitor in type II hyperlipoproteinaemia. Lancet (1982) 0.92
Normal ranges of modified axial lead system electrocardiogram parameters. Br Heart J (1971) 0.92
Pathophysiologic assessment of left ventricular hypertrophy and strain in asymptomatic patients with essential hypertension. J Am Coll Cardiol (1989) 0.91
Haemolysis with Björk-Shiley and Starr-Edwards prosthetic heart valves: a comparative study. Thorax (1974) 0.91
Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. Am J Cardiol (1987) 0.91
Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis (1990) 0.90
Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Fragmin in Unstable Coronary Artery Disease. Am J Cardiol (1997) 0.90
Outcomes of transposition of the great arteries in the ear of atrial inflow correction. Heart (1998) 0.90
Health and efficiency: clinical effectiveness dissected. Health Care Anal (1998) 0.90
Cardiovascular effects of a new inotropic agent, U. K. 14275, in patients with coronary heart disease. Br J Clin Pharmacol (1977) 0.88
Congenital hepatic fibrosis. Postgrad Med J (1967) 0.88
A preliminary clinical study of CT1341--a steroid anaesthetic agent. Br J Anaesth (1971) 0.87
Calcium antagonists and endocrine status: lack of effect of oral verapamil on pituitary-testicular and pituitary-thyroid function. Br J Clin Pharmacol (1984) 0.87
The prevalence of left ventricular hypertrophy in elite professional footballers. Int J Cardiol (1999) 0.87
The determination of carotid intima medial thickness in adults--a population-based twin study. Atherosclerosis (2003) 0.87
Significance of ventricular arrhythmias in systemic hypertension with left ventricular hypertrophy. Am J Cardiol (1992) 0.86
Beta-adrenoreceptor blockade in hypertension. Am J Med (1976) 0.86
Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction. J Int Med Res (1976) 0.86
Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J Lipid Res (1986) 0.85
Auditing the implementation of SIGN (Scottish Intercollegiate Guidelines Network) clinical guidelines. Int J Health Care Qual Assur Inc Leadersh Health Serv (1999) 0.85
The Björk-Shiley tilting disc valve prosthesis. Echocardiographic findings. Scand J Thorac Cardiovasc Surg (1975) 0.85
Lipoprotein levels in apparently healthy men and women in the west of Scotland. Br Heart J (1976) 0.85
Increased titres of anti-human heat shock protein 60 predict an adverse one year prognosis in patients with acute cardiac chest pain. Heart (2005) 0.84
Symptomatic and silent myocardial ischaemia in hypertensive patients with left ventricular hypertrophy. Br Heart J (1992) 0.84
A new surgical approach to myocardial revascularization--internal mammary artery to coronary vein anastomosis. Thorax (1973) 0.84
Failure of single dose amoxycillin as prophylaxis against endocarditis. Br Med J (Clin Res Ed) (1984) 0.84
CABG in the elderly: the Glasgow experience. Gerontology (1989) 0.84
Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins. J Lipid Res (1995) 0.83
Pre-dosing antibody levels and efficacy of thrombolytic drugs containing streptokinase. Br Heart J (1994) 0.83
Epileptiform seizures and electroencephalographic abnormalities as manifestations of digoxin toxicity. Br Med J (Clin Res Ed) (1982) 0.83
CT diagnosis of traumatic pericardium rupture. J Comput Assist Tomogr (1989) 0.83
Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest (1984) 0.83
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects. Atherosclerosis (1982) 0.82
Noninvasive assessment of the haemodynamic effects of nicardipine in normotensive subjects. Br J Clin Pharmacol (1985) 0.82
Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. Br J Clin Pharmacol (1994) 0.82
The pharmacokinetics of R- and S-tocainide in patients with acute ventricular arrhythmias. Br J Clin Pharmacol (1986) 0.82
Induced ventricular tachycardia and fibrillation by a fixed rate pacemaker. The fibrillation threshold in humans. Case report. J Cardiovasc Surg (Torino) (1973) 0.81
Walk or run? Is high-intensity exercise more effective than moderate-intensity exercise at reducing cardiovascular risk? Scott Med J (2011) 0.81
A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica (1984) 0.81
Felodipine extended release in mild to moderate hypertension. Curr Med Res Opin (1991) 0.81
Systolic time intervals in thyroid disease. Clin Endocrinol (Oxf) (1975) 0.81
Combined drug therapy for familial hypercholesterolemia. Artery (1980) 0.81
An influence of variation in the aldosterone synthase gene (CYP11B2) on corticosteroid responses to ACTH in normal human subjects. Clin Endocrinol (Oxf) (2001) 0.81